Portal de Periódicos da CAPES

Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer

2021; Impact Journals LLC; Volume: 12; Issue: 1 Linguagem: Inglês

10.18632/oncotarget.27855

1949-2553

Krastan B. Blagoev, Roumen Iordanov, Mengxi Zhou, Tito Fojo, Susan E. Bates,

Cancer Genomics and Diagnostics

// Krastan B. Blagoev 1 , 2 , Roumen Iordanov 3 , Mengxi Zhou 4 , 5 , Tito Fojo 4 , 5 and Susan E. Bates 4 , 5 1 National Science Foundation, Alexandria, VA 22230, USA 2 Department of Biophysics, Johns Hopkins University, Baltimore, MD 21218, USA 3 Jackson Memorial Hospital, Department of Internal Medicine, Miami, FL 33136, USA 4 Department of Medicine, Division of Hematology/Oncology, Columbia University Medical Center, New York, NY 10032, USA 5 James J. Peters Veterans Affairs Medical Center, Bronx, NY 10032, USA Correspondence to: Krastan B. Blagoev, email: krastan@jhu.edu Keywords: drug resistance; metastatic prostate cancer; exponential growth; tumor kinetics; cancer stem cells Received: September 23, 2020 Accepted: November 12, 2020 Published: January 05, 2021 Copyright: © 2021 Blagoev et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Most metastatic cancers develop drug resistance during treatment and continue to grow, driven by a subpopulation of cancer cells unresponsive to the therapy being administered. There is evidence that metastases are formed by phenotypically plastic cancer cells with stem-cell like properties. Currently the population structure and growth dynamics of the resulting metastatic tumors is unknown. Here, using scaling analysis of clinical data of tumor burden in patients with metastatic prostate cancer, we show that the drug resistant, metastasis-causing cells (MCC) are capable of producing drug resistant, exponentially growing tumors, responsible for tumor growth as a patient receives different treatments.